Efficacy and safety of empagliflozin in older patients in the EMPA-REG OUTCOME® trial

OBJECTIVE: The risks of cardio-renal complications of diabetes increase with age. In the EMPA-REG OUTCOME® trial, empagliflozin reduced cardiovascular (CV) mortality by 38% in patients with type 2 diabetes (T2D) and CV disease. Here we compare outcomes with empagliflozin in older patients in EMPA-RE...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Age Ageing
Asıl Yazarlar: Monteiro, Pedro, Bergenstal, Richard M, Toural, Elvira, Inzucchi, Silvio E, Zinman, Bernard, Hantel, Stefan, Kiš, Sanja Giljanovic, Kaspers, Stefan, George, Jyothis T, Fitchett, David
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Oxford University Press 2019
Konular:
Research Paper
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7963112/
https://ncbi.nlm.nih.gov/pubmed/31579904
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ageing/afz096
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller